SG50479A1 - Stabilized pharmaceutical composition and stabilizing solvent - Google Patents

Stabilized pharmaceutical composition and stabilizing solvent

Info

Publication number
SG50479A1
SG50479A1 SG1996002365A SG1996002365A SG50479A1 SG 50479 A1 SG50479 A1 SG 50479A1 SG 1996002365 A SG1996002365 A SG 1996002365A SG 1996002365 A SG1996002365 A SG 1996002365A SG 50479 A1 SG50479 A1 SG 50479A1
Authority
SG
Singapore
Prior art keywords
solvent
pharmaceutical composition
carboxylate anion
stabilized pharmaceutical
anion content
Prior art date
Application number
SG1996002365A
Other languages
English (en)
Inventor
Shreerham Narahari Agharkar
Uday S Gogate
Thomas Cavanak
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22433231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG50479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG50479A1 publication Critical patent/SG50479A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG1996002365A 1993-09-29 1994-09-27 Stabilized pharmaceutical composition and stabilizing solvent SG50479A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12802693A 1993-09-29 1993-09-29

Publications (1)

Publication Number Publication Date
SG50479A1 true SG50479A1 (en) 1998-07-20

Family

ID=22433231

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996002365A SG50479A1 (en) 1993-09-29 1994-09-27 Stabilized pharmaceutical composition and stabilizing solvent

Country Status (28)

Country Link
US (1) US5504102A (ja)
EP (1) EP0645145B1 (ja)
JP (1) JP3447386B2 (ja)
KR (1) KR100515631B1 (ja)
CN (1) CN1140297C (ja)
AT (1) ATE149843T1 (ja)
AU (1) AU686651B2 (ja)
BE (1) BE1007987A5 (ja)
BR (1) BR1100361A (ja)
CA (1) CA2132936C (ja)
CY (1) CY2035A (ja)
CZ (2) CZ287358B6 (ja)
DE (1) DE69402022T2 (ja)
DK (1) DK0645145T3 (ja)
ES (2) ES2098842T3 (ja)
FI (1) FI115825B (ja)
GR (1) GR3023583T3 (ja)
HK (1) HK96797A (ja)
HU (1) HU217962B (ja)
IL (1) IL111065A (ja)
IT (1) IT1279383B1 (ja)
NO (1) NO308447B1 (ja)
NZ (1) NZ264526A (ja)
PL (1) PL176826B1 (ja)
RU (1) RU2107500C1 (ja)
SG (1) SG50479A1 (ja)
TW (1) TW406020B (ja)
ZA (1) ZA947482B (ja)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
DE19983660T1 (de) * 1998-10-20 2001-09-13 Ben Venue Lab Inc Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
AR027714A1 (es) * 2000-03-24 2003-04-09 Baker Norton Pharma Uso de sales metalicas para estabilizar composiciones de taxanos.
WO2001076559A1 (en) 2000-04-10 2001-10-18 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
EP1280557B1 (en) 2000-05-12 2012-06-20 Samyang Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
EP1313466A4 (en) * 2000-08-02 2005-11-23 Atossa Healthcare Inc BIMODAL EMULSIONS OF TAXANES AND BUTYRATE POLYALCOHOL ESTERS
US6410059B1 (en) * 2000-10-20 2002-06-25 Council Of Scientific And Industrial Research Pharmaceutical composition containing cow urine distillate and an antibiotic
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
EA006741B1 (ru) 2000-11-09 2006-04-28 Неофарм, Инк. Липидная композиция, содержащая производное камптотецина (варианты), способ её получения и применение
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
DK1349545T3 (da) 2000-12-05 2009-02-16 Los Angeles Childrens Hospital Farmaceutiske præparater af fenretinid med öget biotilgængelighed samt fremgangsmåder til anvendelse deraf
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
AU2002305099A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty alcohol drug conjugates
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7141251B2 (en) 2001-04-06 2006-11-28 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
KR20030023369A (ko) * 2001-09-13 2003-03-19 한국과학기술연구원 화학색전용 파클리탁셀 유성 조성물, 그의 제형 및 제조방법
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
AU2002351169B2 (en) * 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
ES2321083T3 (es) * 2002-07-15 2009-06-02 Alcon, Inc. Pelicula bioerosionable para la administracion oftalmica de farmacos.
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
AU2003290647A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
WO2004043390A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
EP1624896B1 (de) * 2003-05-19 2009-07-29 Ebewe Pharma Ges.m.b.H. Nfg. KG Verfahren zur herstellung einer stabilen injizierbaren formulierung von paclitaxel
RU2236852C1 (ru) * 2003-06-23 2004-09-27 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
EP1648988A1 (en) * 2003-07-24 2006-04-26 Dabur Research Foundation Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
ES2325506T3 (es) * 2003-12-12 2009-09-07 Quiral Quimica Do Brasil Procedimiento para la preparacion de principios activos farmaceuticos (api) anhidros e hidratados; composiciones farmaceuticas estables preparadas a partir de los mismos y usos de dichas composiciones.
CA2548078C (en) * 2003-12-17 2009-05-12 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US8242165B2 (en) * 2006-10-26 2012-08-14 Creighton University Mucoadhesive nanoparticles for cancer treatment
EP2962731A1 (en) 2008-01-08 2016-01-06 Bristol-Myers Squibb Company Combination of ipilimumab and paclitaxel for the treatment of cancer
CN101939001B (zh) * 2008-02-20 2012-06-20 埃科特莱茵药品有限公司 用于治疗卵巢癌的含有紫杉醇的组合
DE102008059201A1 (de) 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
KR101733255B1 (ko) 2009-07-20 2017-05-08 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 상승작용적 치료를 위한 항­ctla4 항체와 다양한 치료 요법의 조합
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
WO2012063182A1 (en) * 2010-11-08 2012-05-18 Cadila Pharmaceuticals Limited Pharmaceutical composition of taxoids
WO2014028704A1 (en) * 2012-08-15 2014-02-20 Yung Shin Pharm. Ind. Co., Ltd. Stable pharmaceutical formulation of cabazitaxel
RU2015137815A (ru) * 2013-02-05 2017-03-13 1ГЛОУБ ХЕЛТ ИНСТИТЬЮТ ЭлЭлСи Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
WO2016005962A2 (en) * 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830002614B1 (ko) * 1980-04-14 1983-05-30 후로인도 산교오 가부시끼 가이샤 활성화된 의약조성물의 제법
JPS61152621A (ja) * 1984-12-27 1986-07-11 Lion Corp 液状透明口腔用組成物
RO92831B1 (ro) * 1985-07-29 1988-01-01 Viorica Dobrescu Procedeu de purificare a polietilenglicolilor
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
JPH02196789A (ja) * 1989-01-25 1990-08-03 Sankyo Co Ltd リゾキシン類化合物の安定化法
JP2598206B2 (ja) * 1992-07-17 1997-04-09 ツヤック株式会社 蛋白繊維品のハイグラル・エクスパンションの安定化法
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
KR100371062B1 (ko) * 1992-11-27 2003-04-21 에프.에이치.포울딩 앤드 컴퍼니 리미티드 안정성이향상된주사가능한택솔조성물및이를제형화하는방법

Also Published As

Publication number Publication date
JPH07179362A (ja) 1995-07-18
ZA947482B (en) 1995-05-15
ES2098842T3 (es) 1997-05-01
NO943583L (no) 1995-03-30
CZ287485B6 (cs) 2000-12-13
HU9402776D0 (en) 1994-12-28
CN1107367A (zh) 1995-08-30
RU2107500C1 (ru) 1998-03-27
PL305240A1 (en) 1995-04-03
BR1100361A (pt) 2000-07-18
GR3023583T3 (en) 1997-08-29
RU94037231A (ru) 1996-09-27
FI115825B (fi) 2005-07-29
ITRM940621A1 (it) 1996-03-28
PL176826B1 (pl) 1999-07-30
AU7427394A (en) 1995-04-13
IL111065A0 (en) 1994-12-29
IL111065A (en) 2003-03-12
NO308447B1 (no) 2000-09-18
AU686651B2 (en) 1998-02-12
BE1007987A5 (fr) 1995-12-05
ITRM940621A0 (it) 1994-09-28
KR100515631B1 (ko) 2005-12-08
FI944448A0 (fi) 1994-09-26
US5504102A (en) 1996-04-02
EP0645145A3 (en) 1995-05-24
ATE149843T1 (de) 1997-03-15
ES2095802A1 (es) 1997-02-16
HK96797A (en) 1997-08-08
CZ234994A3 (en) 1995-04-12
DK0645145T3 (da) 1997-04-07
IT1279383B1 (it) 1997-12-10
NZ264526A (en) 1996-10-28
DE69402022T2 (de) 1997-07-17
CZ287358B6 (en) 2000-11-15
HUT68687A (en) 1995-07-28
JP3447386B2 (ja) 2003-09-16
TW406020B (en) 2000-09-21
CA2132936C (en) 1999-06-29
HU217962B (hu) 2000-05-28
DE69402022D1 (de) 1997-04-17
NO943583D0 (no) 1994-09-27
FI944448A (fi) 1995-03-30
CN1140297C (zh) 2004-03-03
EP0645145B1 (en) 1997-03-12
EP0645145A2 (en) 1995-03-29
CA2132936A1 (en) 1995-03-30
CY2035A (en) 1998-02-20
KR950007872A (ko) 1995-04-15

Similar Documents

Publication Publication Date Title
CY2035A (en) Stabilized pharmaceutical composition and stabilizing solvent
AU4081089A (en) Morphine-containing composition
IL90052A (en) :-substituted 4-(quinolin- 2-yl-methoxy) phenylacetic acids and esters, their preparation and pharmaceutical compositions containing them
CA2149150A1 (en) Injectable taxol composition with improved stability
DE3065342D1 (en) Chromium acetylacetonate as a dietary supplement and pharmaceutical agent
DE59307733D1 (de) Kosmetische und dermatologische Formulierungen mit einem wirksamen Gehalt an cis-Urocaninsäure
AU617998B2 (en) Anticoccidial composition
KR950702561A (ko) 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs)
EP0345598A3 (de) Zytostatisch wirksame Anthracyclinderivate
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
JPS56104813A (en) Composition for rectal infusion containing compound having beta-lactam ring
JPS6450816A (en) Isosorbide nitrate agent for transcutaneous use
IE780530L (en) Anti-histamine salts and compositions
TH13516A (th) องค์ประกอบเภสัชกรรม